Coherus Oncology, Inc.
CHRS
$1.13
-$0.04-3.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -302.24% | -120.85% | 111.98% | 99.79% | 88.89% |
| Total Depreciation and Amortization | -22.08% | 10.72% | 39.17% | 40.44% | 20.19% |
| Total Amortization of Deferred Charges | 72.79% | 72.79% | 72.79% | 200.88% | 37.23% |
| Total Other Non-Cash Items | 164.01% | 172.05% | -222.04% | -258.91% | -197.78% |
| Change in Net Operating Assets | -90.71% | 301.07% | 251.78% | 107.90% | 167.71% |
| Cash from Operations | -9.15% | 100.33% | 88.31% | 76.33% | 77.82% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -105.69% | -96.88% | 67.33% | 1,072.07% | 535.94% |
| Cash from Investing | -105.56% | -96.95% | 59.24% | 1,400.36% | 542.42% |
| Total Debt Issued | -100.38% | -- | -- | -- | -24.99% |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -98.34% | -98.73% | -96.79% | -96.23% | -78.96% |
| Repurchase of Common Stock | 90.40% | -28.63% | 30.97% | 17.49% | 16.23% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.04% | 6,647.48% | 3,632.79% | 3,122.46% | 2,733.82% |
| Cash from Financing | 99.89% | -382.12% | -368.64% | -346.40% | -254.56% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -189.21% | -172.87% | -41.80% | 108.35% | 142.62% |